Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$51.45M-1,849%
Zymeworks logo
ZymeworksZYME
$203.13M+1,911%
Charles River Laboratories logo
Charles River LaboratoriesCRL
-$17.8M-168%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.02B-54.5%

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
ADMA Biologics (ADMA) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of $50.52M in Q1 2026.
How has ADMA Biologics's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
ADMA Biologics's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation increased by 260.3% year-over-year, from -$31.52M to $50.52M.
What does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation mean?
Measures the net change in the total liquidity position, including unrestricted cash, cash equivalents, and restricted cash balances over a specific period. This metric is a key indicator of the company's overall cash flow health and liquidity management.